Funding profile · Oncolytic virus therapeutics

Humane Genomics

A preclinical oncolytic virus company that has disclosed two dollar figures in six years: a $125,000 Y Combinator seed check in 2021 and a $70,510 investment vehicle that surfaced in SEC filings in March 2025. Its 2025 Series Seed round, led by Union Square Ventures, has no disclosed size.

$125KY Combinator seed funding, 2021, reported by Fierce Biotech
$70.5KRaised by a Gaingels SPV from 11 investors, filed Mar 2025
UndisclosedSeries Seed amount, led by Union Square Ventures, Feb 2025, company reported

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2021 Y Combinator seed $125,000 Y Combinator Independent
Feb 2025 Series Seed Not disclosed Led by Union Square Ventures Company release
Filed Mar 17, 2025 SPV: Gaingels Humane Genomics LLC $70,510 of $70,510 offered 11 investors; administered by Gaingels Management LLC Form D

What the filings show

Gaingels Humane Genomics LLC · Form D · filed Mar 17, 2025

First sale
Mar 3, 2025
Type
Pooled investment fund (single-company SPV)
Offered
$70,510 equity
Sold
$70,510 · $0 remaining
Investors
11 · average about $6,410, all accredited
Exemption
Rule 506(b)
Related persons
Paul Grossinger, executive officer; Manager of Gaingels Management LLC, which manages the issuer
Filing
SEC EDGAR, CIK 0002055148

Reading the filings

  1. The only Form D on record names a syndicate, not the company.A full text search of EDGAR for “Humane Genomics” and Form D returns exactly one filing, and it is Gaingels Humane Genomics LLC, an investment vehicle organized in Vermont in 2025, not Humane Genomics, Inc. itself. No filing under the operating company’s own name was found.
  2. The vehicle is small and fully subscribed.Eleven investors put in $70,510 total, about $6,410 each, and none of the offering was left unsold. That size and structure is typical of an angel syndicate riding into a round rather than a lead check.
  3. Timing lines up with the Series Seed.The SPV’s first sale, March 3, 2025, and its Form D filing, March 17, 2025, landed about three weeks after Humane Genomics said in mid-February 2025 that it had closed a Series Seed round led by Union Square Ventures. The vehicle’s name and timing suggest it is a small pool of investors riding alongside that round, though the filing does not say so directly.
  4. Two rounds, no dollar figure between them.Neither the company’s own announcement nor the independent outlet FinSMEs, which separately covered the story, put a number on the Series Seed. That leaves the $70,510 SPV filing and the 2021 YC figure of $125,000 as the only two public dollar amounts tied to this company’s fundraising.
  5. No non-dilutive funding turned up.Searches of NSF and NIH award databases under the company’s name did not surface any grants. Two PubMed-indexed papers list company-affiliated authors, but the sources gathered here do not identify what, if anything, funded that work.

Commercial signals

Signal Detail Source type
Manufacturing Process transfer and cGMP manufacturing partnership with Genezen for lead candidate HGI627, announced Nov 12, 2025. Company-stated
Research partner Texas Children’s Hospital named as a research collaborator on the hepatoblastoma program since at least 2021. Company-stated
Conference presence Poster presented at AACR 2025 on preclinical Hep3B xenograft data; company’s third AACR appearance. Company-stated
Clinical trials No trial registered under the company or HGI627. Not found
Regulatory No FDA 510(k), PMA or IND-related public record found. Not found

What to watch

  • A Form D or other public financing record filed directly under Humane Genomics, Inc., with a disclosed dollar amount for the Series Seed.
  • Whether Union Square Ventures or other Series Seed investors are named individually.
  • Progress from the Genezen manufacturing partnership toward an IND filing.
  • Whether the company raises a priced round with its own EDGAR filing as HGI627 advances.

The Humane Genomics story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Ochre Bio: Shared investor: Gaingels. An Oxford company that designs RNA drugs and tests them in whole human donor livers kept alive on machines
  • Alixia: Shared investor: Gaingels. A San Francisco drug discovery company that treats a tumor as an ecosystem rather than as a single mutation
  • Dorian Therapeutics: Shared investor: Gaingels. A Stanford spinout that built small molecule blockers of USP16, the enzyme that strips a silencing mark off histone H2A, and pointed them at the arthritic knee
  • Parallel Bio: Shared investor: Gaingels. Miniature human lymph nodes, grown from donated tissue and run side by side across hundreds of donors, used to test drugs and vaccines before anyone takes them

Sources

  1. Public recordForm D, Gaingels Humane Genomics LLC, CIK 0002055148SEC EDGAR · filed Mar 17, 2025
  2. IndependentHumane Genomics is 3D-printing oncolytic viruses to treat rare cancersFierce Biotech, Amirah Al Idrus · Aug 27, 2021
  3. IndependentHumane Genomics Raises Seed FundingFinSMEs · Feb 18, 2025
  4. IndependentHumane Genomics company profileY Combinator · accessed Sep 25, 2026
  5. CompanyAnnouncing our Series Seed financinghumanegenomics.com blog · Feb 12, 2025
  6. CompanyShowcasing data on our oncolytic viral therapy at AACR 2025humanegenomics.com blog · Apr 22, 2025
  7. CompanyGenezen Announces Manufacturing Partnership with Humane Genomics to Advance Oncolytic Virus Therapy for Pediatric Liver CancerPR Newswire · Nov 12, 2025

Compiled from SEC and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Humane Genomics. This page is not an offer to sell or a recommendation to buy any security.